Core Points - The company held its fifth extraordinary general meeting of shareholders on November 7, 2025, with no resolutions being rejected [2][4] - All proposed resolutions were approved during the meeting, including a resolution to provide guarantees for a controlling company and to reappoint the accounting firm [4][5] - The meeting was presided over by the chairman, Michael MingYan Liu, and attended by all nine current directors and key executives [3][4] Fundraising Information - The company successfully raised a total of RMB 1,075,950,160.00 from its initial public offering (IPO) in 2020, with a net amount of RMB 978,057,381.28 after deducting issuance costs [10] - In a subsequent issuance, the company raised RMB 213,999,988.12, with a net amount of RMB 203,920,127.60 after related expenses [12] - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [14] Account Cancellation - The company decided to cancel a special fundraising account at Shanghai Pudong Development Bank due to the completion of the use of excess funds from the IPO [15] - The cancellation of the account has been completed, and the corresponding regulatory agreement has been terminated [15]
上海三友医疗器械股份有限公司 2025年第五次临时股东会决议公告